| 瞿小应,杜旋.STS联合吉非替尼对NSCLC患者血小板活化功能及炎症因子的影响.[J].中南医学科学杂志.,2021,(5):523-527. |
| STS联合吉非替尼对NSCLC患者血小板活化功能及炎症因子的影响 |
| Effects of sodium tanshinone ⅡA sulfonate combined with gefitinib on platelet activation and inflammatory factors in patients with advanced non-small cell lung cancer |
| 投稿时间：2020-11-04 修订日期：2020-12-08 |
| DOI：10.15972/j.cnki.43-1509/r.2021.05.006 |
| 中文关键词: 丹参酮ⅡA磺酸钠 吉非替尼 晚期非小细胞肺癌 血小板活化功能 炎症因子 |
| 英文关键词:STS gefitinib NSCLC platelet activation function inflammatory factor |
| 基金项目:湖北省卫计委科研项目(WJ2015MB260) 作者简介:瞿小应,主治医师,研究方向为肿瘤血液疾病的防治,E-mail为yc_qxy@163.com。 |
|
| 摘要点击次数: 350 |
| 全文下载次数: 282 |
| 中文摘要: |
| 目的研究丹参酮ⅡA磺酸钠(STS)对吉非替尼治疗晚期非小细胞肺癌(NSCLC)患者血小板活化功能及炎症因子的影响。方法选取晚期NSCLC患者110例,其中吉非替尼组55例行吉非替尼治疗,联合STS组55例行吉非替尼联合STS治疗,比较两组患者客观疗效、生存质量、炎症因子水平、免疫功能、血小板活化功能指标水平及不良反应发生情况。比较随访期两组患者客观生存率和生存时间。结果联合STS组治疗总有效率、疾病控制率、生存质量改善率均明显高于吉非替尼组(P＜0.05)。两组治疗后白细胞介素-6、肿瘤坏死因子-α、超敏C反应蛋白、P-选择素、溶酶体颗粒糖蛋白、血小板激活复合物-1等水平均较治疗前显著降低(P＜0.05),且联合STS组明显低于吉非替尼组(P＜0.05)。联合STS组免疫球蛋白A、免疫球蛋白G、免疫球蛋白M水平明显高于吉非替尼组(P＜0.05)。联合STS组肝功能异常和血小板减少等不良发生率明显低于吉非替尼组(P＜0.05)。随访期联合STS组和吉非替尼组客观生存率比较差异无显著性(P＞0.05),联合STS组生存时间明显长于吉非替尼组(P＜0.05)。结论STS能够提高吉非替尼治疗晚期NSCLC的临床疗效及生存质量,抑制血小板聚集和活化,降低炎症因子水平,改善免疫功能,降低不良反应发生率。 |
| 英文摘要: |
| To study the effect of sodium tanshinone ⅡA sulfonate (STS) on platelet activation and inflammatory factors in patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib. Methods110 patients with advanced NSCLC were selected, 55 cases in gefitinib group were treated with gefitinib, and 55 cases in STS group were treated with gefitinib combined with STS. The objective efficacy, quality of life, levels of inflammatory factors, immune function, platelet activation function and adverse reactions of the two groups were compared. Objective survival rate and survival time were compared between the two groups during the follow-up period. ResultsThe effective rate, disease control rate and improvement rate of quality of life in the combined STS group were significantly higher than those in the gefitinib group (P＜0.05). After treatment, the levels of interleukin-6, tumor necrosis factor-α, high sensitivity C-reactive protein, P-selectin, lysosomal granule glycoprotein and platelet activating complex-1 in the two groups were significantly lower than those before treatment (P＜0.05), and the levels in the combined STS group were significantly lower than those in the gefitinib group (P＜0.05). The levels of immunoglobulin A, immunoglobulin G and immunoglobulin M in combined STS group were significantly higher than those in gefitinib group (P＜0.05). The incidence of liver dysfunction and thrombocytopenia in the combined STS group was significantly lower than that in the gefitinib group (P＜0.05). There was no significant difference in the objective survival rate between the combined STS group and gefitinib group during the follow-up period (P＞0.05). The survival time of the combined STS group was significantly longer than that of the gefitinib group (P＜0.05). ConclusionSTS can improve the clinical efficacy and quality of life of gefitinib in the treatment of advanced NSCLC, inhibit platelet aggregation and activation, reduce the level of inflammatory factors, improve immune function and reduce the incidence of adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|